Hosted on MSN16d
MGRM: Monogram’s Potential for 2025 Commercialization of its mBôs Total Knee Arthroplasty Robotic System Supports Price Target of $6.00.MGRM READ THE FULL MGRM RESEARCH REPORT Regulatory Update On February 26, 2025, Monogram (NASDAQ:MGRM) announced an update regarding its 510(k) premarket filing submission to the FDA for the company's ...
Monogram Technologies provided an update regarding its 510(k) premarket filing submission to the U.S. Food and Drug Administration for the ...
Company has Completed all Supplemental Testing and has Submitted its Formal Response to the FDA’s Additional Information Request (AIR) ...
Completed all Supplemental Testing and has Submitted its Formal Response to the FDA’s Additional Information Request (AIR) ...
Monogram Technologies Inc. (NASDAQ:MGRM) (”Monogram” or the “Company”), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced ...
Monogram has obtained FDA clearance for mPress implants and applied for 510(k) clearance for its robotic products. The Company is required to obtain FDA clearance before it can market its products.
("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today provided an update regarding its 510(k) premarket ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback